MICHAEL ENG: Open Payments
NPI 1053882076 · CORONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,406 in 124 payments from 40 companies in 2025. Trend: 2023 $0 · 2024 $3,090 · 2025 $3,406
Food & beverage: $3,328Education: $78
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $284 |
| Novartis Pharmaceuticals Corporation | 11 | $278 |
| AstraZeneca Pharmaceuticals LP | 9 | $255 |
| Janssen Biotech, Inc. | 8 | $206 |
| Incyte Corporation | 7 | $190 |
| SOBI, INC | 6 | $144 |
| Daiichi Sankyo Inc. | 5 | $134 |
| GENZYME CORPORATION | 5 | $130 |
| Eisai Inc. | 5 | $112 |
| Karyopharm Therapeutics Inc. | 4 | $108 |
Products named: ENHERTU, KEYTRUDA, JAKAFI, IMFINZI, PLUVICTO, Lenvima, XPOVIO, SARCLISA.
Industry payments across CA — which companies pay providers there.
